Synopsis: Emcure Pharma shares surged over 7% after announcing a strategic partnership with Novo Nordisk to distribute and commercialise Poviztra (second brand of Wegovy) in India, expanding access to semaglutide based weight loss therapy across wider markets.
The shares of this company that manufactures and markets a broad range of pharmaceutical and biopharmaceutical products across a wide range of dosage forms, including oral solids, oral liquids, injectables etc is now in the focus after it partnered with Novo Nordisk from weight loss drug distribution.
With market capitalization of Rs. 27,488 cr, the shares of Emcure Pharmaceuticals Ltd are currently trading at Rs. 1,449 per share, increasing more than 7% in today’s market session making a high of Rs. 1,463.70 per share, from its previous close of Rs. 1,362.40 per share.
India faces a major obesity burden with 254 million people with generalised obesity and 351 million with abdominal obesity. It leads to 230+ related health complications and significant socio-economic impact. Obesity is not just lifestyle related, but driven by multiple factors like genetics, biology, psychology and environment and needs long-term clinical management like other chronic diseases.
News
Novo Nordisk India has partnered with Emcure Pharma to commercialise Poviztra, the second brand of Wegovy (semaglutide injection 2.4 mg) for weight loss in India. With this, Emcure becomes the first Indian pharma company to get exclusive rights to distribute and market this molecule domestically.
The strategic collaboration aims to expand access to semaglutide beyond currently served regions, enabling wider reach through stronger pharmacy penetration across India, especially for patients dealing with overweight and obesity.
Emcure CEO Satish Mehta said the company is proud to partner with Novo Nordisk to bring Poviztra to India, backed by strong global semaglutide clinical evidence and long real-world exposure data. He said Emcure’s distribution strength will help expand access to patients across India who need this molecule the most. Poviztra (semaglutide) is a once-weekly injection used for chronic weight management and to reduce cardiovascular risk in adults with obesity or overweight with comorbidities. It comes in multiple dose strengths including a 2.4 mg maintenance dose.
Novo Nordisk India is the Indian affiliate of global healthcare major Novo Nordisk A/S, Denmark. The company focuses on addressing chronic diseases like diabetes, obesity and rare disorders through innovation, expanded access to medicines and scientific advancement. Globally, Novo Nordisk operates in 80 countries with products marketed across around 170 countries.
About the company
Emcure Pharmaceuticals Ltd. (EPL) is a leading Indian pharma company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. Known for its commitment to innovation, quality, and patient-centricity, Emcure is an R&D driven company that develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas.
The company delivers a ROCE of 20.7% and ROE of 18.5%. It has also managed to reduce its debt levels. The stock is currently trading at a P/E of 36.5 compared to the industry average P/E of 32.8.
The sales of the company decreased from Rs. 2,116 cr in Q4FY25 to Rs. 2,101 cr in Q1FY26. Operating profit fell to Rs. 417 cr from Rs. 402 cr. Net profit rose from Rs. 197 cr to Rs. 215 cr over the same period.
Written by Manideep Appana
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
